• Explore /
  • Poster
  • / Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients.

Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients.

Abstract Poster

Authors

Abraham Leung

Abraham C.F. Leung

Dynavax Technologies, Berkeley, CA

Abraham C.F. Leung , Shivaani Kummar , Sanjiv S. Agarwala , John J. Nemunaitis , Rene Gonzalez , Joseph J. Drabick , Emmett V. Schmidt , Elliot Chartash , Biao Xing , Graeme Currie , Robert Janssen , Antoni Ribas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02521870

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9550)

DOI

10.1200/JCO.2017.35.15_suppl.9550

Abstract #

9550

Poster Bd #

158

Abstract Disclosures

Similar Posters

First Author: Anthony W. Tolcher

First Author: Timothy Jay Price

First Author: Jason Alan Chesney

First Author: Jorge D. Oldan